Cannabis & female fertility

TL;DR

• Chronic THC use can delay or inhibit ovulation (Mendelson 1986; Klonoff-Cohen 2006).
• Endocannabinoids (anandamide) play a central role in implantation.
• IVF studies: THC users show lower fertilization rates.
• When trying to conceive: fully avoid THC.

Mechanisms in detail

Anandamide levels drive uterine receptivity. THC disturbs this balance and can lower implantation chances.

THC also modulates the hypothalamic-pituitary axis (LH suppression).

Endocannabinoid system and germ cell maturation

The endocannabinoid system is a fundamental regulator of human reproduction. Cannabinoid receptors that react to the body's own messenger substances are located in the ovaries as well as in the fallopian tube and the endometrium. If this highly sensitive system is disrupted by the consumption of exogenous cannabinoids such as tetrahydrocannabinol, this can impair the maturation of the oocytes. The precise control necessary for the selection and development of a healthy oocyte is thrown out of balance. This can reduce the quality of the oocytes and decrease the likelihood of successful fertilization at an early stage.

In addition to oocyte maturation, the endocannabinoid system plays a crucial role in transporting the fertilized oocyte through the fallopian tube. A disrupted cannabinoid balance can negatively affect motility, i.e. the movement of the fallopian tube. This increases the risk that the oocyte does not implant in the uterus in a timely manner or, in the worst-case scenario, implants outside the uterus. Since these processes are highly coordinated, specialists advise a consistent period of abstinence when trying to conceive, in order to fully restore the body's own regulation and minimize the risk of early pregnancy complications.

• Presence of cannabinoid receptors throughout the female genital tract
• Disruption of local signaling pathways by exogenous cannabinoids such as THC
• Possible reduction in oocyte quality prior to fertilization
• Risk of impaired transport of the oocyte in the fallopian tube

Swiss context: Medical consultation, law and prevention

In Switzerland, the topic of fertility and cannabis consumption is closely monitored by medical professionals and federal authorities such as the Federal Office of Public Health (FOPH). Although medical cannabis has been easier to prescribe since the amendment of the law in August 2022, Swiss doctors consistently advise abstinence when planning a pregnancy or during pregnancy. Since THC-containing products with a total THC content of over one percent fall under the Narcotics Act, recreational use during this phase of life is also highly relevant from both a legal and health perspective, particularly with regard to youth protection and infant health.

In Swiss road traffic, a strict zero-tolerance policy also applies, with a limit of 1.5 micrograms of THC per liter of blood. Since the metabolites of THC are fat-soluble and accumulate in the tissue, detection can remain positive long after the last consumption. For couples planning a family, this means that abstinence not only protects biological fertility but also minimizes legal risks in everyday life. Swiss counseling centers and Tox Info Suisse offer evidence-based education to inform expectant parents about the long-lasting effects in the body.

• Strict recommendation of abstinence by Swiss medical professionals and the FOPH when trying to conceive
• Medical cannabis prescription requires a careful benefit-risk assessment
• Consideration of the strict Swiss road traffic regulations regarding residual THC in the body
• Fat solubility of THC leads to long-term storage in the tissue
• Educational services provided by cantonal specialist centers and Tox Info Suisse

Cannabidiol (CBD) and reproduction: The current state of evidence

While the harmful effects of THC on fertility are relatively well documented, the scientific data on cannabidiol (CBD) remains incomplete but cautionary. Since CBD also interacts with the endocannabinoid system, an influence on the reproductive organs cannot be ruled out. Swiss laboratories and international studies indicate that even CBD-rich products, even if they are below the legal limit of one percent THC, could disrupt cellular communication in the ovaries. Precautionary abstinence is therefore also advisable for supposedly harmless CBD products.

Another risk with CBD products is the lack of standardisation and potential contamination. Since the market for CBD products is diverse, they may contain traces of heavy metals, pesticides, or indeed small amounts of THC, which accumulate in the body with regular consumption. For women planning a pregnancy, this represents an unpredictable burden. Precautionary avoidance of all cannabis-based substances is the safest way to protect reproductive health and create optimal conditions for successful conception and healthy fetal development.

• Limited but cautionary data regarding CBD and fertility
• Possible interaction of CBD with the reproductive organs despite the lack of psychoactivity
• Risk of accumulating pollutants or incompletely declared traces of THC in products
• Recommendation to avoid all cannabinoids during the family planning phase

FAQ